Table 1.
Differentially expressed plasma, serum, and salivary miRNAs in patients with endometriosis.
| Author, Reference | Sample | miRNAs | Methods | Sensitivity and Specificity (%) | Stage of Disease |
|---|---|---|---|---|---|
| Wang et al., 2013 [57] | Serum | miR-199a ↑ miR-122 ↑ miR-9 ↓ miR-145 ↓ miR-141 ↓ miR-542-3p ↓ |
Taqman miRNA array; validation qRT-PCR with Sybr Green | 78.33 and 76.00 80.00 and 76.00 68.33 and 96.00 70 and 96 71.69 and 96.00 79.66 and 92.00 |
I/II/III/IV |
| Jia et al., 2013 [56] | Plasma | miR-17-5p ↓ miR-20a ↓ miR-22 ↓ |
Agilent human microRNA microarray; validation qRT-PCR with Sybr Green | 70.0 and 70.0 60.0 and 90.0 90.0 and 80.0 |
III/IV |
| Suryawanshi et al., 2013 [59] | Plasma | miR-16 ↑ miR-191 ↑ miR-195 ↑ |
RT-qPCR profiling (human MiRNome profiler kit); validation qRT-PCR with Sybr Green | 88 and 60 | NA |
| Hsu et al., 2014 [60] | Serum | miR-199a-5p ↓ | Microarray; validation Taqman qRT-PCR | NA | NA |
| Cho et al., 2015 [43] | Serum | Let-7b ↓ miR-135a ↓ |
qRT-PCR with Sybr Green | NA NA |
III/IV |
| Rekker et al., 2015 [54] | Plasma | miR-200a ↓ miR-141 ↓ |
Taqman qRT-PCR | 90.6 and 62.5 71.9 and 70.8 |
I/II/III/IV |
| Cosar, et al., 2016 [61] | Serum | miR-125b-5p ↑ miR-451a ↑ miR-3613-5p ↓ |
Affymetrix microRNA microarray and qRT-PCR with Sybr Green | 100 and 96 NA NA |
III/IV |
| Wang et al., 2016 [62] | Serum | miR-185-5p ↑ miR-424-3p ↑miR-15b-5p ↓ miR-20a-5p ↓ miR-30c-5p ↓ miR-99b-5p ↓ miR-127-3p ↓ |
Solexa sequencing and qRT-PCR with Sybr Green | NA | I/II |
| Pateisky et al., 2018 [63] | Plasma | hsa-miR-154-5p ↓ | qPCR-based arrays | 67 and 68 | I/II/III/IV |
| Bashti et al., 2018 [58] | Plasma | miR-31 ↓ miR-145 ↑ |
qRT-PCR | - | I/II/III/IV |
| Nisenblat et al., 2019 [35] | Plasma | miR-139-3p ↓ miR-155 ↓ miR-574-3p ↓ |
Multiplex RT-qPCR and singleplex Taqman RT-qPCR |
70 and 57 67 and 60 73 and 53 |
I/II/III/IV |
| Vanhie et al., 2019 [41] | Plasma | hsa-miR-125b-5p hsa-miR-28-5p hsa-miR-29a-3p |
Small RNA-seq and RT-qPCR with Sybr Green | 78 and 37 | I/II/III/IV |
| Moustafa et al., 2020 [53] | Serum | miR-125b ↑ miR-150 ↑ miR-342 ↑ miR-451 ↑ miR-3613 ↓ let-7b ↓ |
qRT-PCR with Sybr Green |
56.1 and 78.0 20.0 and 94.7 90.0 and 91.2 90.0 and 72.9 92.7 and 61.0 82.5 and 67.8 |
I/II/III/IV |
| Zhang et al., 2020 [64] | Serum exosomes | miR-22-3p ↑ miR-320a ↑ |
Agilent human microRNA microarray and TaqMan qRT-PCR | NA | I/II/III/IV |
| Misir et al., 2021 [39] | Serum | miR-34a-5p ↓ miR-200c ↑ |
qRT-PCR | 78.95 and 49.12 100 and 100 |
I/II/III/IV |
| Bendifallah et al., 2022 [55] | Plasma | A signature composed of 86 miRNAs | Small RNA-seq | 96.8 and 100 | I/II/III/IV |
| Bendifallah et al., 2022 [48] | Saliva | A signature composed of 109 miRNAs | Small RNA-seq | 96.7 and 100 | I/II/III/IV |
↑: indicates upregulated miRNAs. ↓: indicates downregulated miRNAs. N/A: Data not available.